Your search for apixaban returned 51 results

Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).

Apixaban and rivaroxaban are both factor Xa inhibitors.

Older patients, females, and those with comorbidities were more likely to be on multiple medications.

If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.

Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.

This is an investigational use for Eliquis.

For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is beneficial and appropriate for those with one dose-reduction criterion, according to a study published online in JAMA Cardiology.

Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.

Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA’s Accelerated Approval pathway.

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.